y Cambridge Biotech Corp. has launched a second-generation enzymeimmunoassay to diagnose Clostridium difficile, a major cause ofantibiotic-associated diarrhea and colitis. Results of the test can be readin 1.5 hours, half the time of the first generation test. The Worcester,Mass.-based company markets the only diagnostic that detects bothToxin A and Toxin B, causative factors of this gastrointestinalcondition.y Dianon Systems, Inc., of Stratford, Conn., signed a productdevelopment and licensing agreement with Centocor, Inc., of Malvern,Pa., to develop new diagnostic assay technologies. Dianon will assignmanufacturing and marketing rights to Centocor of the new assaytechnology and receive royalty payments on worldwide sales of theproducts.y Elan Corp., of Athlone, Ireland, and Dura Pharmaceuticals, Inc., ofSan Diego, signed a definitive stock purchase agreement under whichElan will purchase 343,857 shares of Dura stock for $3 million. Elanwill acquire a warrant to purchase 300,000 additional shares of Duracommon stock at $8.75 per share, exercisable during a seven-yearperiod beginning six months after purchase. The collaboration centers,in part, on Dura's propriety pulmonary drug delivery technologyknown as Dryhaler.
(c) 1997 American Health Consultants. All rights reserved.